ANYINKE ATABONG: Open Payments
NPI 1316359771 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,116 in 89 payments from 21 companies in 2025. Trend: 2023 $2,945 · 2024 $4,749 · 2025 $4,116
Food & beverage: $2,636Consulting: $1,480
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $1,480 |
| ABBVIE INC. | 15 | $402 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $279 |
| Otsuka America Pharmaceutical, Inc. | 9 | $268 |
| Neurocrine BioSciences, Inc. | 4 | $267 |
| Alkermes, Inc. | 6 | $259 |
| Supernus Pharmaceuticals, Inc. | 6 | $208 |
| E.R. Squibb & Sons, L.L.C. | 3 | $159 |
| Lundbeck LLC | 8 | $158 |
| Lilly USA, LLC | 6 | $119 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, Qelbree, ABILIFY MAINTENA, REXULTI, COBENFY, ARISTADA.
Industry payments across MD — which companies pay providers there.
